Monitor GSK's commercial launch execution and initial prescription data for HIBSAGO, as well as upcoming regulatory decisions in ex-US geographies which could trigger milestone payments to Ionis.
Price Chart
Executive Summary
Ionis Pharmaceuticals' partner GSK announced FDA approval of HIBSAGO (bepirovirsen) for chronic hepatitis B, a first-in-class RNA-targeted medicine. Phase 3 data showed a 19% functional cure rate vs <1% for standard of care. Ionis receives tiered royalties of 10-12% on net sales and is eligible for additional milestone payments.
Key Facts
- FDA approved HIBSAGO (bepirovirsen) for chronic hepatitis B under priority review and Breakthrough Therapy Designation
- Phase 3 B-Well trials showed 19% functional cure rate (233/1,220) vs <1% for standard of care
- Ionis receives tiered royalties of 10-12% on net sales of bepirovirsen
- GSK licensed bepirovirsen from Ionis in 2019; Ionis has received upfront, license fee, and development/regulatory milestone payments
- GSK advancing regulatory submissions globally with key decisions expected in coming months
Financial Impact
Ionis eligible for tiered royalties of 10-12% on net sales plus additional regulatory and sales milestone payments; no specific dollar amounts disclosed
Risk Factors
- Boxed warning for on-treatment hepatic flares and thrombocytopenia may limit adoption
- Narrow indicated population (non-cirrhotic, HBsAg ≤3000 IU/ml) restricts addressable market
- Competition from other HBV functional cure candidates in development
- Royalty rate (10-12%) is modest relative to typical biotech licensing deals
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-040388 |
| Document: ef20084189_ex99-1.htm | 0001140361-26-040388 |
| Document: 0001140361-26-040388-index-headers.html | 0001140361-26-040388 |
| Document: 0001140361-26-040388-index.html | 0001140361-26-040388 |
| Document: 0001140361-26-040388.txt | 0001140361-26-040388 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $42.93 | awaiting T+20 | — | $43.51 (+1.35%) |
Oct 21, 2026 5d ago | 8-K | $43.91 | awaiting T+20 | — | $43.51 (−0.91%) |
Oct 21, 2026 5d ago | Institutional Cluster | $43.91 | awaiting T+20 | — | $43.51 (−0.91%) |
Sep 23, 2026 4w ago | 8-K | $43.93 $44.27 | ▲ +0.77% | ▲ +0.09% | $43.51 (−0.96%) |
Sep 4, 2026 7w ago | 8-K | $56.71 $44.00 | ▲ +22.41% | ▲ +24.13% | $43.51 (+23.28%) |
Sep 4, 2026 7w ago | 8-K | $58.09 $43.50 | ▼ −25.12% | ▼ −25.72% | $43.51 (−25.10%) |
Jul 31, 2026 12w ago | Insider Buy | $54.49 $60.36 | ▲ +10.77% | ▲ +9.53% | $43.51 (−20.15%) |
Jul 29, 2026 12w ago | 8-K | $54.04 $63.36 | ▲ +17.25% | ▲ +12.23% | $43.51 (−19.49%) |
Jul 9, 2026 15w ago | 8-K | $58.25 $56.56 | ▼ −2.90% | ▼ −5.33% | $43.51 (−25.30%) |
Jul 9, 2026 15w ago | Insider Cluster | $58.25 $56.56 | ▼ −2.90% | ▼ −5.33% | $43.51 (−25.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers